FDA eases limits on drug promotion

被引：0

|

作者：

不详

机构：

来源：

CHEMICAL & ENGINEERING NEWS | 2008年 / 86卷 / 08期

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

收藏

页码：32 / 32

页数：1

相关论文

共 50 条

[21] TRENDS IN FDA DRUG PROMOTION ENFORCEMENT LETTERS OVER A TEN-YEAR PERIOD
Zagrodney, K.
Sheikhan, T.
Sheikhan, N. Y.
Pinto, A. M.
Witek, T.
VALUE IN HEALTH, 2017, 20 (09) : A662 - A662
[22] UK eases drug reclassification process
不详
CHEMISTRY & INDUSTRY, 2002, (10) : 10 - 10
[23] THE LIMITS TO HEALTH PROMOTION
STOTT, NCH
KINNERSLEY, P
ROLLNICK, S
BMJ-BRITISH MEDICAL JOURNAL, 1994, 309 (6960): : 971 - 972
[24] THE OUTER LIMITS OF FDA INSPECTIONS
SCARLETT, T
JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, 1991, 45 (04): : 204 - 208
[25] THE FDA LIMITS THE DOSAGE OF SIMVASTATIN
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2011, 111 (10) : 22 - 23
[26] The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"
Wanasika, Isaac
INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2016, 5 (06): : 391 - 392
[27] FDA proposes easing of promotion rules
Barnett, AA
LANCET, 1996, 347 (8993): : 52 - 52
[28] Panel eases US drug approval process
Susman, E
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) : 630 - 630
[29] Panel eases US drug approval process
Susman, E
LANCET ONCOLOGY, 2004, 5 (02): : 71 - 71
[30] FDA CONSIDERS LEAD LIMITS FOR LIPSTICK
不详
CHEMICAL & ENGINEERING NEWS, 2012, 90 (08) : 31 - 31

← 1 2 3 4 5 →